Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients
Author(s) -
Giora Weisz,
Nathaniel R. Smilowitz,
Ajay J. Kirtane,
Michael J. Rinaldi,
Rupa Parvataneni,
Ke Xu,
Thomas Stuckey,
Akiko Maehara,
Bernhard Witzenbichler,
FranzJosef Neumann,
D. Christopher Metzger,
Timothy D. Henry,
David A. Cox,
Peter L. Duffy,
Bruce R. Brodie,
Ernest L. Mazzaferri,
Roxana Mehran,
Gregg W. Stone
Publication year - 2015
Publication title -
circulation cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.621
H-Index - 95
eISSN - 1941-7632
pISSN - 1941-7640
DOI - 10.1161/circinterventions.114.001952
Subject(s) - clopidogrel , medicine , p2y12 , cardiology , odds ratio , concomitant , hazard ratio , drug eluting stent , myocardial infarction , percutaneous coronary intervention , confidence interval
Certain proton pump inhibitors (PPIs) interfere with clopidogrel metabolism, potentially attenuating P2Y12 receptor inhibition. Previous observational and randomized trials report conflicting results regarding the clinical significance of this pharmacological interaction. We examined the interaction between concomitant administration of PPI and clopidogrel on platelet reactivity and clinical outcomes in the large-scale, prospective Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents study.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom